Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Denali Therapeutics Inc (DNLI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/27/2025: DNLI (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
19 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $32.19
1 Year Target Price $32.19
| 15 | Strong Buy |
| 4 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -25.89% | Avg. Invested days 35 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/27/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.05B USD | Price to earnings Ratio - | 1Y Target Price 32.19 |
Price to earnings Ratio - | 1Y Target Price 32.19 | ||
Volume (30-day avg) 19 | Beta 1.33 | 52 Weeks Range 10.57 - 33.33 | Updated Date 06/30/2025 |
52 Weeks Range 10.57 - 33.33 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.65 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -22.58% | Return on Equity (TTM) -35.21% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1263121423 | Price to Sales(TTM) 3643.65 |
Enterprise Value 1263121423 | Price to Sales(TTM) 3643.65 | ||
Enterprise Value to Revenue 2843.16 | Enterprise Value to EBITDA -8.66 | Shares Outstanding 145276000 | Shares Floating 130572885 |
Shares Outstanding 145276000 | Shares Floating 130572885 | ||
Percent Insiders 9.97 | Percent Institutions 94.28 |
Analyst Ratings
Rating 4 | Target Price 32.19 | Buy 4 | Strong Buy 15 |
Buy 4 | Strong Buy 15 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Denali Therapeutics Inc
Company Overview
History and Background
Denali Therapeutics Inc. was founded in 2015 and focuses on developing therapies for neurodegenerative diseases. It went public in 2017. The company is headquartered in South San Francisco, California.
Core Business Areas
- Neurodegenerative Diseases: Denali focuses on discovering and developing therapies for neurodegenerative diseases like Alzheimer's, Parkinson's, ALS, and others.
- Transport Vehicle Platform: Denali's Transport Vehicle (TV) platform allows the delivery of therapeutic antibodies and enzymes across the blood-brain barrier.
Leadership and Structure
Ryan Watts is the CEO. The company has a board of directors and operates with a research and development focus, organized into functional areas like drug discovery, clinical development, and manufacturing.
Top Products and Market Share
Key Offerings
- Takeda Collaboration Program: Denali has entered into a license agreement and research collaboration with Takeda to discover, develop, and commercialize new therapies for neurodegenerative diseases. Details around revenue generated from this collaboration will be available within Takeda's reporting. Competitors include companies with similar collaboration strategies like Biogen.
- SAR443954 (DNL151): An investigational RIPK1 inhibitor being developed in collaboration with Biogen for Amyotrophic Lateral Sclerosis (ALS). As an investigational drug, no current revenue is generated. Competitors in ALS treatment development include Amylyx Pharmaceuticals and Biogen.
- Etanercept (DNL758): Etanercept is an experimental treatment for systemic lupus erythematosus (SLE). No current revenue is generated as the drug is still in clinical trials. Competitors include GlaxoSmithKline with Benlysta.
Market Dynamics
Industry Overview
The neurodegenerative disease market is large and growing, driven by an aging population and increasing prevalence of diseases like Alzheimer's and Parkinson's. Significant unmet needs exist, creating a high demand for new therapies.
Positioning
Denali is a leader in developing therapies that can cross the blood-brain barrier, giving it a competitive advantage. However, the clinical success rate in neurodegenerative diseases is low, posing a risk.
Total Addressable Market (TAM)
The global market for neurodegenerative diseases is projected to reach hundreds of billions of USD. Denali is positioned to capture a significant portion through its innovative transport vehicle technology and pipeline of therapies.
Upturn SWOT Analysis
Strengths
- Proprietary Transport Vehicle (TV) technology
- Strong pipeline of novel therapies
- Strategic partnerships with major pharmaceutical companies (Biogen, Takeda)
- Experienced management team focused on neurodegenerative diseases
Weaknesses
- High R&D costs and long development timelines
- Clinical trial risks and regulatory hurdles
- Dependence on partnerships for funding and development
- No currently marketed products, meaning no product revenue
Opportunities
- Expanding pipeline through internal discovery and external collaborations
- Targeting multiple neurodegenerative diseases with high unmet need
- Leveraging the TV platform for other therapeutic areas
- Potential for breakthrough therapies to generate significant revenue
Threats
- Clinical trial failures
- Competition from other companies developing neurodegenerative disease therapies
- Regulatory setbacks
- Patent challenges
- Economic downturn affecting research funding
Competitors and Market Share
Key Competitors
- BIIB
- LLY
- VRTX
Competitive Landscape
Denali's strength lies in its Transport Vehicle technology. Its weakness is the lack of marketed products compared to Biogen (BIIB) and Eli Lilly (LLY).
Growth Trajectory and Initiatives
Historical Growth: Denali has experienced significant growth in its pipeline and partnerships since its founding.
Future Projections: Analysts expect revenue to increase significantly with potential drug approvals and milestone payments. Losses are expected to continue in the near term due to high R&D expenses.
Recent Initiatives: Recent initiatives include expanding the pipeline, advancing clinical trials, and strengthening partnerships.
Summary
Denali Therapeutics is a promising biotech company focused on neurodegenerative diseases. Its innovative Transport Vehicle technology and strong partnerships are significant strengths. However, the company faces clinical trial risks and high R&D costs, requiring careful management and successful execution to deliver long-term value.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. Market share data is approximate and may vary based on source and definition.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Denali Therapeutics Inc
Exchange NASDAQ | Headquaters South San Francisco, CA, United States | ||
IPO Launch date 2017-12-08 | Co-Founder, President, CEO & Director Dr. Ryan J. Watts Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 443 | |
Full time employees 443 | |||
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; DNL343 eIF2B activator program for amyotrophic lateral sclerosis; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome). Its Enzyme TransportVehicle (TV) programs include DNL952 for the treatment of Pompe disease; DNL111 for Parkinson's and Gaucher diseases; and DNL622 for Hurler syndrome (MPS I). The company's OTV programs also comprise DNL628 targeting tau for Alzheimer's disease; and DNL422 targeting alpha synuclein for Parkinson's disease, as well as antibody TV program includes DNL921 targeting Abeta for treating Alzheimer's disease. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.